Edition:
United Kingdom

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

7.28USD
19 Jun 2018
Change (% chg)

$-0.01 (-0.14%)
Prev Close
$7.29
Open
$7.25
Day's High
$7.44
Day's Low
$7.03
Volume
35,682
Avg. Vol
40,061
52-wk High
$21.59
52-wk Low
$4.78

Chart for

About

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to... (more)

Overall

Beta: --
Market Cap(Mil.): $110.31
Shares Outstanding(Mil.): 10.63
Dividend: --
Yield (%): --

Financials

  GEMP.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -2.65 -- --
ROI: -580.12 1.56 14.38
ROE: -3,285.30 2.43 16.07

BRIEF-Gemphire Therapeutics Reports Q1 Loss Per Share Of $0.58

* GEMPHIRE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 May 2018

BRIEF-Gemphire Therapeutics Names Steven Gullans CEO

* GEMPHIRE THERAPEUTICS ANNOUNCES THE APPOINTMENT OF STEVEN GULLANS, PH.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

03 May 2018

BRIEF-Gemphire Therapeutics Reports Qtrly Loss Per Share $0.63‍​

* GEMPHIRE THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

15 Mar 2018

Earnings vs. Estimates